Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain

被引:11
作者
Park, SH
Kang, SH
Lim, SH
Oh, HS
Lee, KH
机构
[1] Inha Univ, Dept Chem, Inchon 402751, South Korea
[2] Mogam Biotechnol Res Inst, Signal Transduct Lab, Kyunggi, South Korea
关键词
D O I
10.1016/S0960-894X(03)00735-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
On the basis of the structure of (R)-rosmarinic acid, a series of small chemical compounds with a different scaffold was synthesized as inhibitors for lck SH2 domain. From ELISA results, most of all chemical compounds showed a similar or a little lower binding activity for lck SH2 domain compared to the lead compound, (R)-rosmarinic acid. It was characterized that the backbone rigidity between two catechol substructures was required for the full activity and acid substructure of the lead compound was important for the activity. We successfully identified novel lead compounds that did not contain phosphotyrosine moiety and might have an improved bioavailability as inhibitor for lck SH2 domain. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3455 / 3459
页数:5
相关论文
共 21 条
[1]  
Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124
[2]   Ligands for the tyrosine kinase p56lck SH2 domain:: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements [J].
Beaulieu, PL ;
Cameron, DR ;
Ferland, JM ;
Gauthier, J ;
Ghiro, E ;
Gillard, J ;
Gorys, V ;
Poirier, M ;
Rancourt, J ;
Wernic, D ;
Llinas-Brunet, M ;
Betageri, R ;
Cardozo, M ;
Hickey, ER ;
Ingraham, R ;
Jakes, S ;
Kabcenell, A ;
Kirrane, T ;
Lukas, S ;
Patel, U ;
Proudfoot, J ;
Sharma, R ;
Tong, L ;
Moss, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (10) :1757-1766
[3]   A non-enzymatic synthesis of (S)-(-)-rosmarinic acid and a study of a biomimetic route to (+)-rabdosiin [J].
Bogucki, DE ;
Charlton, JL .
CANADIAN JOURNAL OF CHEMISTRY, 1997, 75 (12) :1783-1794
[4]  
Botfield M.C., 1995, ANN REP MED CHEM, V30, P227, DOI [10.1016/S0065-7743(08)60937-9, DOI 10.1016/S0065-7743(08)60937-9]
[5]  
Broadbridge R. J., 2000, Current Drug Targets, V1, P365, DOI 10.2174/1389450003349074
[6]  
CACA MP, 1985, TETRAHEDRON, V41, P5061
[7]   ONCOGENES AND SIGNAL TRANSDUCTION [J].
CANTLEY, LC ;
AUGER, KR ;
CARPENTER, C ;
DUCKWORTH, B ;
GRAZIANI, A ;
KAPELLER, R ;
SOLTOFF, S .
CELL, 1991, 64 (02) :281-302
[8]  
Eicher T, 1996, SYNTHESIS-STUTTGART, P755
[9]   Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70 [J].
García-Echeverría, C .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (13) :1589-1604
[10]  
GILLES G, 2000, TETRAHEDRON LETT, V41, P1553